Tyrpsine kinase inhibitors (TKIs) effectively target progenitors and mature leukaemic cells but prove less effective at eliminating leukaemic stem cells (LSCs) in patients with chronic myeloid leukaemia (CML). Several reports indicate that the TGFβ superfamily pathway is important for LSC survival and quiescence. We conducted extensive microarray analyses to compare expression patterns in normal haemopoietic stem cells (HSC) and progenitors with CML LSC and progenitor populations in chronic phase (CP), accelerated phase (AP) and blast crisis (BC) CML. The BMP/SMAD pathway and downstream signalling molecules were identified as significantly deregulated in all three phases of CML. The changes observed could potentiate altered autocrine signal...
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends ...
がん進展制御研究所Although discovery of the tyrosine kinase inhibitor (TKI) imatinib mesylate has significant...
The identification of BCR-ABL1 as the key molecular event in chronic myeloid leukemia (CML) has revo...
Leukaemic stem cell (LSC) persistence remains a major obstacle to curing chronic myeloid leukaemia (...
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder characterized by the presenc...
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder characterized by the presenc...
Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm characterised by the presence of Ph...
Chronic myeloid leukemia disease (CML) found effective therapy by treating patients with tyrosine ki...
CML (chronic myeloid leukaemia) is a myeloproliferative disease that originates in an HSC (haemopoie...
Although tyrosine kinase inhibitors (TKIs) are effective in treating chronic myeloid leukemia (CML),...
Chronic myeloid leukaemia (CML) is characterised by the presence of the fusion protein BCR-ABL1. The...
Background Despite improved patient outcome using tyrosine kinase inhibitors (TKIs), chronic myeloid...
Background & aims: In CML, Leukemic Stem Cells (LSCs) that are insensitive to Tyrosine Kinase Inhibi...
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends ...
CML (chronic myeloid leukaemia) is characterized by the presence of the oncogenic tyrosine kinase fu...
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends ...
がん進展制御研究所Although discovery of the tyrosine kinase inhibitor (TKI) imatinib mesylate has significant...
The identification of BCR-ABL1 as the key molecular event in chronic myeloid leukemia (CML) has revo...
Leukaemic stem cell (LSC) persistence remains a major obstacle to curing chronic myeloid leukaemia (...
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder characterized by the presenc...
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder characterized by the presenc...
Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm characterised by the presence of Ph...
Chronic myeloid leukemia disease (CML) found effective therapy by treating patients with tyrosine ki...
CML (chronic myeloid leukaemia) is a myeloproliferative disease that originates in an HSC (haemopoie...
Although tyrosine kinase inhibitors (TKIs) are effective in treating chronic myeloid leukemia (CML),...
Chronic myeloid leukaemia (CML) is characterised by the presence of the fusion protein BCR-ABL1. The...
Background Despite improved patient outcome using tyrosine kinase inhibitors (TKIs), chronic myeloid...
Background & aims: In CML, Leukemic Stem Cells (LSCs) that are insensitive to Tyrosine Kinase Inhibi...
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends ...
CML (chronic myeloid leukaemia) is characterized by the presence of the oncogenic tyrosine kinase fu...
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends ...
がん進展制御研究所Although discovery of the tyrosine kinase inhibitor (TKI) imatinib mesylate has significant...
The identification of BCR-ABL1 as the key molecular event in chronic myeloid leukemia (CML) has revo...